

calcium release following stimulation with glutamate. Glutamate dose dependently decreased cell viability and increased the level of $[Ca^{2+}]_i$. However, the cells pretreated with dantrolene, an inhibitor of calcium release through RyR located in endoplasmic reticulum (ER), substantially lowered glutamate-induced increase of $[Ca^{2+}]_i$ and cell damages in neuronal cells. Moreover, dantrolene also inhibited $[Ca^{2+}]_i$ released through RyR in PC12 cells expressing mutant presenilin-2, which seems to be a modulator of calcium signal in ER. Our data therefore suggest that alternation of $[Ca^{2+}]_i$ through RyR in ER could be significantly important in neuronal cell damages by glutamate.

Poster Presentations – Field A2. Therapeutics

[PA2-1] [04/17/2003 (Thr) 14:00 – 17:00 / Hall P]

An improved method to determine hydroxyproline in an immortalized rat liver stellate cell line (HSC-T6)

Lee EunSu^o, *Kwak Wie-Jong Kwak, **Lee Eung-Seok, Soh Yunjo

Graduate School of East-West Medical Science, Kyung Hee University: *Life Science Center, SK chemicals;**College of Pharmacy, Yeungnam University

Hydroxyproline (HYP) is a post-translational product of proline hydroxylation catalyzed by an enzyme prolyl 4-hydroxylase which plays a crucial role in the synthesis of all collagens, because the 4-hydroxyproline residues are essential for the folding of the newly synthesized collagen polypeptide chains into triple-helical molecules. Considering the role of collagen and its significance in many clinically important diseases such as liver cirrhosis, a great deal of attention has been directed toward the development of an assay at cell-based system. The numerous assay procedures described for HYP are laborious, time-consuming and not feasible for the massive-screening. Here, we report the cell-based assay of prolyl 4-hydroxylase using HSC-T6 cells. To improve the sensitivity of assay for HYP content, ascorbate in hypoxic condition or lactate were added to the media. HOE 077 or pyridine 2,4 dicarboxylic acid, inhibitors of prolyl 4-hydroxylase, exhibited the 75% and 70% of enzyme activity compared to control, respectively. The assay procedure took only 3 days after treatment with agents, while assays from the primary stellate cells or liver tissues have taken several weeks. Considering the time, expenses and trends in assay design from biochemical method to cell-based method, this assay method could be useful tool to screen the compounds for the inhibitor of prolyl 4-hydroxylase. (Supported by The Center for Biological Modulators, 21C Frontier)

[PA2-2] [04/17/2003 (Thr) 14:00 – 17:00 / Hall P]

DW1350, a Newly Synthetic Anti-osteoporotic Agent : 1. DW-1350 Inhibited Bone Resorption and Promoted Bone Formation.

Lee JinSoo*, **Wang YunHa^o*****, Ahn SeokHoon*, PanSoo*, Jin SangMi, Yi SunShin*, Jung YoungHo*, Suh Hongsuk**, Ryu JeiMan*

*Central Research Laboratories, Dong-Wha Pharm. Ind. Co., Ltd, **Department of Chemistry, Pusan National University, ***Biochemistry Department, Seoul National University

Recently, we developed a new anti-osteoporotic agent, DW-1350, which not only inhibited osteoclast formation but also induced osteoblast differentiation through the in vitro randomized screening studies.

We identified inhibitory activities of DW-1350 for each step of osteoclast differentiation, fusion and pit formation process in co-culture system with mouse bone marrow and primary osteoblasts. As a result of these studies, we found that DW-1350 suppressed the formation of TRAP-positive osteoclasts induced by 1 α ,25(OH) $_2$ D $_3$ and dexamethasone. This study also showed that DW-1350 exhibited significant decrease of the fusion process to mature osteoclasts and the bone-resorbing activity measured by pit number formed on dentine slice in a dose-dependent manner. In osteoblastic MC3T3-E1 cell, DW-1350 affected cell proliferation and up-regulated differentiation markers such as alkaline phosphatase (ALP) activity. And we identified the positive effects of DW-1350 on bone nodule formation determined by amount of minerals deposited on the formed bone matrix.

These results suggest that DW-1350 might be a promising agent for treatment of osteoporosis not only by inhibiting osteoclast formation and bone-resorbing action, but also by stimulating osteoblast differentiation.

[PA2-3] [04/17/2003 (Thr) 14:00 - 17:00 / Hall P]

DW1350, a Newly Synthetic Anti-osteoporotic Agent : 2. Effect on Ovariectomized Osteoporosis Rat Model, a Histomorphometrical Aspect.

Lee JinSoo, Ku SaeKwang^o, Jung DaHee, Jin Youngoo, Park JaeHoon, Yang HeeBok, Jung YongHo, Ryu JeiMan

Central Research Laboratories, Dong-Wha Pharm. Ind. Co., Ltd.

In the present study, the effect of DW-1350, a newly synthesized anti-osteoporotic agent, was evaluated in ovariectomized Rat. Female SD Rat mice underwent bilateral ovariectomy for prevention study that test article was administered from 2 days after ovariectomy for 6 weeks, for therapeutic study it was conducted from 6 weeks after ovariectomy for three months. Body weight, bone weight and histological profiles of epiphyseal regions of tibia and femur such as cortical bone thickness, trabecular bone number, thickness and length with trabecular bone volume percentage (TBV), were observed respectively. Results were compared to that of alendronate, well-documented anti-osteoporotic agents. Histomorphometrical changes were observed or calculated using image analyzer system, AnalySIS-auto (SIS Co., Germany). In prevention and therapeutic studies, DW-1350 showed favorable inhibitory effect to histomorphometrical changes induced by ovariectomy. We can also find that DW-1350 dose-dependently (10 or 50mg/kg, *p.o.*) increased the TBV, trabecular bone length and width, and cortical bone width or decreased the osteoclast cell numbers. Especially more favorable effects were observed in DW-1350 compared to that of alendronate on cortical bone thickness. Base on these results, DW-1350 may act as both a suppressor of bone resorption and an enhancer of bone formation *in vivo*. In conclusion, it should be suggested that DW-1350 has enough and favorable effect to prevention and therapy of estrogen-deficient osteoporosis.

[PA2-4] [04/17/2003 (Thr) 14:00 - 17:00 / Hall P]

The protective and antioxidant effect of Solanum lycopersicum extract in liver fibrosis induced rats

Oh Semi^o, Park JunHo, Lee SangHee, Kim HeeSeok, Kim KiYoung, Andrea mattes

Professional Graduate School of Oriental Medicine, Wonkwang University